The Metastatic Melanoma Cancer Diagnostics Market To Be Backed By Technological Innovation In The Next Decade

The Metastatic Melanoma Cancer Diagnostics Market, at a CAGR of 7.7% between 2021-2031, is bound to reach US$ 2.9 Bn. With technology scaling new heights, it’s inevitable for health systems to integrate with the existing technology platforms. Also, geographical barriers are done away with telehealth to add. The care delivery solutions are not expected to be the same going forward. EHR will continue to expand with the addition of NLP, voice, and digital assistance. As such, it could be inferred that hi-tech healthcare solutions would be the future of the healthcare arm.

The Metastatic Melanoma Cancer Diagnostics Market will probably reach US$ 2.9 Bn between 2021-2031 at the rate of 7.7%. The healthcare vertical is witnessing consolidation at a rapid pace as value-based care is on the anvil. With the majority of key participants opting for an inorganic mode of expansion, it has been observed that nearly every single business day witnesses this on paper. This riding on inorganic growth is bound to keep the healthcare vertical happening throughout.

The rising prevalence of metastatic melanoma cancer has been witnessed over the years. Verified therapeutics and diagnostics have a positive impact on treating the disease and extending the life span of patients. Improving sophistication in healthcare facilities and technological developments across the world are key factors expanding the market for metastatic melanoma cancer diagnostics. Government initiatives related to creating awareness for early diagnosis and treatment are also expected to drive demand for metastatic melanoma cancer diagnostics.

Get Sample Copy of Report @

The global metastatic melanoma cancer diagnostics market is estimated to be valued at US$ 2.9 Bn in 2021, and exhibit a CAGR of close to 8% over the forecast period (2021 – 2031).

Key Takeaways from Market Study

  • PET scan test holds the highest value share in the market under products, owing to advantages such as it shortens test time and provides accurate attenuation correction and fusion imaging, leading to an increase in diagnostic sensitivity and specificity.
  • By service provider, pathology laboratories hold a notable revenue share of more than half in the market.
  • Owing to rising cancer cases and increased awareness about cancer screening, the pathology laboratories segment is expected to experience lucrative growth among all service providers at a CAGR of 8.5% through 2031.
  • North America accounted for a share of more than 45% in 2020. It is the most lucrative market among all regions and is expected to experience significant growth over the next ten years.
  • Europe is the next dominating region with a market share of 35% in 2020, due to the flourishing cancer diagnostics industry in the region.

“Rising prevalence of metastatic melanoma disorders, increasing demand for non-invasive diagnostic therapy, and developments in metastatic melanoma cancer are is expected to drive market growth,” says a Persistence Market Research analyst.

Request for Methodology @

COVID-19 Impact

According to the American Society of Clinical Oncology, the COVID-19 disease has tremendously disrupted healthcare facilities, globally. COVID-19 has also led to disruption in cancer services. The pandemic has resulted in heavy reduction in diagnosis, non-elective surgeries, and non-essential medical visits. Delay in visits for diagnosis can lead to delay in treatment for melanoma and other skin cancers, leading to serious health issues. All in all, the market witnessed sluggish growth due to the onset of the COVID-19 outbreak. However, as things have opened up, the market is set to recover some of its lost pace over the coming months and years.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the metastatic melanoma cancer diagnostics market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021–2031, based on product (biopsy, chest X-ray, lymphoscintigraphy, ultrasound, CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, and PET (positron emission tomography) scans)) and service provider (hospitals, pathology laboratories, and cancer research centers), across seven key regions of the world.

Access Full Report @

Explore Extensive Coverage of Persistence Market Research’s Healthcare Industry

Related Reports:

Orally Disintegrating Tablet Market:

The global orally disintegrating tablets market was valued at nearly US$ 12 Bn in 2018 and will exhibit a solid CAGR during the forecast period (2019 – 2029).

Disposable Incontinence Products Market:

The global disposable incontinence products market surpassed a value of US$ 9 Bn in 2018, which is set to witness healthy growth during the period of projection (2019 – 2029).

Sleep Aids Market:

A new study of Persistence Market Research (PMR) suggests that global sleep aids market revenues exceeded US$ 23 Bn in 2018 and will exhibit a promising CAGR during the forecast period (2019 – 2029).

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Contact Us:

Persistence Market Research Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353

Sales – [email protected]

Website –